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Abstract Intermittent parathyroid hormone administra-
tion can enhance fracture healing in an animal model.
Despite the success of exogenous parathyroid hormone on
fracture healing and spine fusion, few studies have
examined the role of parathyroid hormone on cartilage
formation. We determined the effects of intermittent para-
thyroid hormone on cartilage formation in a rabbit micro-
fracture model of cartilage regeneration. Twelve rabbits
were divided into three equal groups: (1) microfracture
alone, (2) microfracture + parathyroid hormone daily for
7 days, and (3) microfracture + parathyroid hormone for
28 days. Nonoperated contralateral knees were used as
controls. The animals were sacriﬁced at 3 months and gross
and histologic analysis was performed. The microfracture
alone group demonstrated the most healing on gross and
histologic analysis. Treatment with either 1 or 4 weeks of
parathyroid hormone inhibited cartilage formation.
Although discouraging from a cartilage repair point of
view, this study suggests that the role parathyroid hormone
administration has in clinical fracture healing must be
examined carefully. Although parathyroid hormone is
beneﬁcial to promote healing in spine fusion and midshaft
fractures, its deleterious effects on cartilage formation
suggests that it may have adverse effects on the outcomes
of periarticular fractures such as tibial plateau injuries that
require cartilage healing for a successful clinical outcome.
Keywords parathyroidhormone.cartilage.microfracture
Introduction
Full-thickness cartilage defects remain one of the most
common, yet difﬁcult challenges faced by orthopedic
surgeons today. Curl et al. [1] reported in over 31,000 knee
arthroscopies that 63% of patients had a grade III or IV
[2, 3] articular cartilage lesion. These lesions demonstrate
limited healing potential, with full-thickness cartilage
lesions healing with both types I and II cartilage, and lower
than normal concentrations of proteoglycans [4]. The
formation of structurally inferior ﬁbrocartilage leads to
premature irregularities of the joint surface over time,
meniscal tears, and, eventually, degenerative arthritis.
Microfracture was developed by Steadman et al. [5]a sa
novel technique to treat full-thickness cartilage lesions. The
technique of microfracture uses an awl to penetrate the
subchondral plate, which leads to migration of mesenchy-
mal stem cells into the cartilage defect and reconstitution of
the injured area with a ﬁbrocartilage repair with varying
amounts of types I, II, and III collagen content [6].
Microfracture reportedly results in 70% to 90% of patients
having short-term improvement in function [5–9]. However,
a small but substantial percentage has only moderate to
poor ﬁll and worse subjective and objective clinical
outcomes [8].
Despite the clinical success of microfracture in
healing small (<2 cm) cartilage defects in the knee [5,
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quality and ﬁll of these lesions. Penetration of the
subchondral bone allows for mesenchymal stem cells to
enter into a localized defect and produce ﬁbrocartilage.
Current surgical techniques typically allow for complete
ﬁll in 54%, partial ﬁll in 29%, and poor ﬁll in 17% [5].
Not surprisingly, there is a correlation between amount
of ﬁll and clinical outcome. As the results of micro-
fracture have been variable, there have been many
attempts to increase the likelihood of complete lesion
ﬁll with hyaline cartilage. Previous animal studies have
utilized bone morphogenetic proteins (BMPs), trans-
forming growth factor-β, and insulin-like growth fac-
tor-1 to stimulate cartilage healing with promising
results [12–14]. In a recent study, Morgan et al. [12]
found BMP-7, which induces cartilage formation,
worked synergistically with microfracture to heal full-
thickness cartilage defects in a rabbit model. Despite the
early success of these studies in animal models, no
recombinant growth factors have been successfully
utilized in clinical trials to our knowledge.
The role of exogenous parathyroid hormone (PTH) in
fracture healing continues to be elucidated. Alkhiary et al.
[15] originally reported that intermittent administration of
PTH enhanced fracture healing in a rat fracture model. The
authors found that treatment with 80 μg/kg PTH increased
callus area and strength, with an increase in the amount of
new bone formed with histologic analysis [15]. Numerous
subsequent studies have found similar results [16–18].
Recent studies have found that there is increased chondro-
genesis with exogenous administration of PTH. Manabe et
al. [17] reported increased expression of SOX9 and
procollagen α-1 and increased chondrocyte proliferation in
animals receiving intermittent PTH. SOX9 is a high-
mobility group domain transcription factor expressed in
chondrocytes during cartilage formation and is essential for
cartilage formation in SOX9
−/− transgenic mice [19].
Expression of SOX9 is decreased in cartilage defects that
failed to heal, highlighting the importance of this
transcription factor in healing of cartilage lesions.
Similarly, Lane et al. [20] reported increased expression of
Wnt 4, 5a, 5b, and 10b in animals treated with intermittent
PTH to stimulate fracture healing. Taken together, these
studies suggest that exogenous PTH stimulates fracture
healing by increasing the activity of genes such as SOX9
and the Wnt family of proteins to increase chondrogenesis
and promote cartilage formation.
The purpose of this study was to evaluate the effects of
exogenous intermittent PTH administration on (1) the gross
and (2) the microscopic cartilage healing in a rabbit
microfracture model. Based on the improved chondro-
genesis seen with the use of PTH in a fracture healing
model, we hypothesized that the same mechanisms would
stimulate improved cartilage formation in a microfracture
setting We speciﬁcally aimed to measure the effect that
exogenous, intermittent PTH administration has following
1- and 4-week treatment periods on the gross and histologic
appearance of cartilage defects treated by microfracture
compared to animals treated with microfracture alone.
Materials and methods
Female adolescent New Zealand White rabbits (n=12),
weighing from 3.1 to 3.5 kg, were utilized for this study.
The animals were divided into three groups: microfracture
alone, microfracture + 10 μg/kg human recombinant (1–34)
PTH for 7 days, and microfracture + 10 μg/kg recombinant
(1–34) PTH for 28 days (Fig. 1). The control group
received a saline injection for 7 days. The PTH was
administered subcutaneously on a daily basis commencing
on the day of surgery and continued until the speciﬁed day.
Standard anteroposterior and lateral radiographs of the
affected knee were obtained at the time of sacriﬁce to identify
any osseous changes. The research protocol was approved by
the animal ethics committee of the Hospital for Special
Surgery and animal care and experimental procedures were
approved by the animal institutional review board.
The rabbit microfracture model has been previously
described [18]. Animals were anesthetized with sodium
pentobarbital and the left leg was prepped and draped.
Sterile procedure was used for every animal. A midline
incision was made over the knee and a medial parapatellar
arthrotomy was performed to expose the knee. The patella
was reﬂected laterally to expose the femoral trochlea. A 6-
mm full-thickness defect was made on the weight-bearing
surface of the trochlea using a curette. Microfracture was
performed with an 18-gauge needle. The microfracture
holes punctured the subchondral plate and blood was seen
to exit each of the holes. The wounds were closed and the
animal was allowed to bear weight immediately. Pain
medication was administered as needed after the procedure.
At the time of sacriﬁce, the animals were given a lethal
dose of sodium pentobarbital. At the sacriﬁce, the soft tissue
was removed from the distal femur, and the femur was
sectioned approximately 1 cm above the joint. The patella
and proximal tibia were removed from the specimen as
well. The contralateral femur was removed as a nonoperated
control. We scored the gross appearance of the lesion based
on the ﬁll of the lesion (1=no ﬁll; 2=minimal ﬁll; 3=near-
complete ﬁll; 4=complete ﬁll), quality of the tissue within
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Fig. 1. a–c Diagrams illustrate the experimental design for the PTH
treatment of 6-mm-diameter full-thickness defects of articular carti-
lage. a Saline was administered as a control, b 10 μg/kg PTH was
administered daily for 1 week, or c 10 μg/kg PTH was administered
daily for 4 weeks. The animals were sacriﬁced at 12 weeks (triangle).
The distal portion of the femur was removed and ﬁxed as described in
“Materials and methods” section
80 HSSJ (2010) 6: 79–84the lesion (1=no tissue; 2=soft tissue within the lesion; 3=
normal appearing tissue within the lesion), and surrounding
changes (1=substantial degenerative cartilage changes
surrounding the lesion with loss of cartilage down to bone;
2=slight changes in the surrounding cartilage without loss
of cartilage to bone; 3=no changes). This allowed for a
calculation of a gross score with a maximum of 10 points.
Following gross examination, the distal femurs were
ﬁxed in 4% paraformaldehyde at room temperature and then
transferred to 10% ethylenediaminetetraacetic acid for
3 weeks for decalciﬁcation. The specimens were then
embedded in parafﬁn for subsequent histologic analysis.
Five-micrometer transverse sections were taken through the
center of the defect and stained with hematoxylin and eosin
or alcian blue. For semiquantitative analysis of cartilage
restoration, we (BF, ZD) examined the sections in a blinded
manner and scored according to the grading scale of Pineda
et al. [11] with modiﬁcations as described by Mizuta et al.
[13] (Table 1). The maximum score with this scale is 14,
indicating complete ﬁll with reconstitution of the osteo-
chondral junction, normal staining of the matrix, and
normal cell morphology.
Data are presented as the mean ± standard deviation.
Differences between groups in both the gross and histologic
score were evaluated with a one-way analysis of variance.
A value of p<0.05 was deﬁned as statistically signiﬁcant.
Results
At the time of sacriﬁce, there were no complications due to
PTH administration, and all animals appeared to tolerate the
treatment well. One animal developed ossiﬁcation around
the knee and a ﬂexion contracture during the last week of
the study. This animal was treated with a microfracture
alone, and therefore, this was not a complication of PTH
administration. Radiographs of this animal showed soft
tissue calciﬁcation surrounding the knee. No other animals
had any important radiographic changes at the time of
sacriﬁce.
Administration of PTH inhibited or delayed the regen-
eration of cartilage in the microfracture sites compared to
the untreated animals. Grossly, all animals in the micro-
fracture alone group appeared to have completely healed
their defects with normal-appearing cartilage in three of
four animals. One animal had cartilage that felt softer than
the other animals. The overall gross score was 9.1±0.8. In
the 1-week PTH group, there was minimal or no new
cartilage present and the defects remained present in all the
animals. One animal had erosive changes surrounding the
lesion. The overall gross score was 2.3±1.4 (p<0.001
versus control). In the 4-week PTH group, there was
minimal cartilage formed in two of the four animals
Table 1 Scoring system for the histological appearance of full-
thickness cartilage defects
Characteristic Score
Defect ﬁll
125% 3
100% 4
75% 3
50% 2
25% 1
0% 0
Reconstitution of osteochondral junction
Yes 3
Almost 2
Not close 1
Matrix staining
Normal 4
Reduced 3
Faint 2
Minimal 1
None 0
Cell morphology
Normal 4
Mostly hyaline and ﬁbrocartilage 3
Mostly ﬁbrocartilage 2
Some ﬁbrocartilage 1
Nonchondrocytic cells only 0
Fig. 2. a–c Photographs show the gross appearance of representative specimens at the time of sacriﬁce. a In the microfracture alone specimen,
there is reconstitution of the lesion with near-complete ﬁll and normal-appearing cartilage. b In the microfracture + 1-week PTH specimen, the
lesion is still clearly evident with minimal ﬁll. In addition, the surrounding cartilage appears to have thinned and undergone erosive changes. c In
the microfracture + 4-week PTH specimen, similar to the 1-week treatment group, the lesion remains evident with minimal ﬁll within the lesion.
There appears to be some mild erosive as well
HSSJ (2010) 6: 79–84 81although the cartilage felt soft. One animal in this group had
substantial erosive changes surrounding the lesion as well.
The overall gross score was 3.6±2.5 (p<0.001 versus
control; p = NS versus 1-week PTH; Fig. 2).
Histologic analysis conﬁrmed the ﬁndings of the gross
analysis further suggesting that PTH administration
inhibited cartilage regeneration in the microfracture sites.
There was near-complete ﬁll of the defect in the micro-
fracture alone group, although there were fewer cells and
reduced matrix staining within the microfracture lesion
compared to control contralateral femurs (Fig. 3a). In the 1-
week PTH group, there was no ﬁll of the lesion and there
appeared to be thinning of the surrounding cartilage in all
the samples (Fig. 3b). Similar results were found in the 4-
week PTH group, with minimal ﬁll of the defect and
thinning of the surrounding cartilage and decreased matrix
staining (Fig. 3c). The average histologic score in the
microfracture alone group was 10.3±3.4, compared to 2.7±
2.5 in the 1-week PTH group (p<0.001 versus micro-
fracture alone) and 3.4±2.5 in the 4-week PTH group (p<
0.001 versus microfracture alone; Fig. 4).
Discussion
Intermittent PTH administration can enhance fracture
healing in an animal model. Despite the success of
exogenous PTH on fracture healing and spine fusion, there
have been few studies examining the role of PTH on
cartilage healing. We investigated the role of intermittent
administration of exogenous recombinant PTH on healing
of a microfracture model. Based on the improved chondro-
genesis seen with the use of PTH in a fracture healing
model, we hypothesized that the same mechanisms would
stimulate improved cartilage healing in a microfracture
setting. Contrary to our hypothesis, we found that inter-
mittent PTH given for 1 or 4 weeks was effective at
inhibiting cartilage production in this model. Although
disappointing from a cartilage repair standpoint, our results
are interesting as it increases our understanding of the role
of PTH in bone and cartilage formation.
There were several weaknesses to this study. First, since
we designed a preliminary study, we used no alternate doses
Fig. 3. a–c Photomicrographs show the histologic appearance of
representative specimens at the time of sacriﬁce (stain, hematoxylin
and eosin, alcian blue; original magniﬁcation, ×10). a In the micro-
fracture alone specimen, there is reconstitution of the lesion with near-
complete ﬁll, although there are fewer than normal cells and the matrix
staining is less than normal. b In the microfracture + 1-week PTH
specimen, the lesion is still clearly evident with minimal ﬁll. In
addition, the surrounding cartilage appears to have thinned with
decreased matrix staining. c In the microfracture + 4-weeks PTH
specimen, no cartilage formation is evident within the lesion, and the
surrounding cartilage appears to be thinned as well
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Fig. 4. A graph shows the histologic score as described by Pineda et
al. [11] for the three treatment groups. †p<0.001 versus control
animals. MFx microfracture
82 HSSJ (2010) 6: 79–84or administration time courses. A dose of 10 µg/kg was
chosen based on its success in previous studies that it found
successfully improved bone formation via chondrogenesis
[17, 18]. Likewise, a 1- and 4-week time course of PTH
administration was chosen based on its success in previous
studies [17, 18]. It is possible that a shorter period of time
(i.e., 2–5 days) would be sufﬁcient to stimulate cartilage
formation without leading to inhibition of osteochondral
healing. Second, the underlying mechanism of inhibition of
cartilage formation with intermittent PTH is not clearly
understood. With continuous PTH administration, there is
downregulation of the PTH/PTH-related protein (PTHrP)
receptors, but it is unknown if intermittent PTH functions
by the same mechanism to inhibit cartilage repair. Clearly,
these factors should be clariﬁed in subsequent studies.
Based on the promising results with other growth factors
and the enhanced chondrogenesis seen using recombinant
intermittent PTH in a fracture healing model, we presumed
that administration of 10 µg/kg intermittent PTH would
enhance cartilage formation in a microfracture model.
However, we found that intermittent PTH actually nearly
completely inhibited the formation of new cartilage within
the defect in our model. With 1 week of PTH, there was no
cartilage formed within the defect, a ﬁnding that was clearly
evident on both gross and histologic examination. The
ﬁndings were similar in animals treated for 4 weeks of
intermittent PTH. On gross examination, there was minimal
or no ﬁll in almost all the animals treated with intermittent
PTH, suggesting an inhibition of chondrocyte proliferation.
A smaller proportion of the animals also demonstrated
adjacent cartilage breakdown after treatment with PTH.
Interestingly, there appeared to be decreased staining of the
surrounding cartilage matrix in those animals treated with
PTH, suggesting an alteration of collagen or proteoglycan
concentration in these animals. These results clearly
demonstrate that intermittent PTH administration is not an
effective means to improve the ability of microfracture to
heal chondral defects.
Two previous studies utilizing continuous PTH admin-
istration in a chondral defect model have demonstrated
results similar to ours. Nozaka et al. [21] reported that PTH,
when given continuously via an osmotic pump into the
knee, completely inhibited chondrogenesis. The authors
found that, although proliferation of the chondral precursors
was normal, PTH administration effectively inhibited
chondrogenic differentiation. In a subsequent study, the
authors found that continuous PTH administration for
4 weeks was able to irreversibly block expression of PTH/
PTHrP receptor, suggesting cells that migrate into the
chondral defect maintain their chondrogenic potential for
no more than 2 weeks [22]. Our data suggest that even
intermittent PTH administration results in a similar outcome
in this model. This is surprising as it is traditionally thought
that continuous and intermittent PTH function in separate
ways in a fracture healing model. These results demonstrate
that it is vital to more completely understand the mecha-
nisms that govern the outcome of PTH administration in
osteochondral injury models. This is particularly true in
cases of fractures that enter the joint. Although it may be
alluring to use PTH to improve fracture healing in these
difﬁcult to treat fracture models, it is possible that the PTH
would have a deleterious effects on the cartilage injury and
result in a much poorer overall outcome.
We found that intermittent PTH did not improve healing
of full-thickness chondral defects in a rabbit microfracture
model and in fact inhibited cartilage formation within the
defect. Although these results did not support our hypoth-
esis, they do highlight the importance of understanding the
molecular mechanisms that govern the relationship between
PTH and chondrogenesis. Future studies focusing on the
molecular mechanisms of PTH-mediated chondrogenesis
and the time course of gene expression may help elucidate
why PTH is effective in stimulating cartilage formation in a
fracture healing model yet is unable to stimulate cartilage in
a full-thickness chondral injury model.
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